S. 4472
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
The bill's own words, as Congress.gov publishes them, without its long title and table of contents.
Sec. 1. Short title This Act may be cited as the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Sec. 2. Reauthorization of Accelerating Access to Critical Therapies for ALS Act
(a) In general Section 7 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117–79) is amended by striking 2022 through 2026 and inserting 2027 through 2031.
This change is to a law outside the US Code: the bill cites it only by Public Law number.
(b) Grants for ALS research Section 2(f) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by striking 2026 and inserting 2031.
This change is to a provision the US Code prints only as a note, not as part of its text.
Sec. 3. Improvements to program for grants for research on therapies for ALS Section 2 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended—
(1) in subsection (a), by inserting (referred to in this section as “expanded access grants”) before the period at the end of the first sentence;
We couldn't place this change in the Code: we can't yet read how this change is worded.
(2) in subsection (b)—
(A) by striking (b) Application— and all that follows through A participating in paragraph (1) and inserting the following:
(b) Application.— A participating
;
We couldn't place this change in the Code: we can't yet read how this change is worded.
(B) by redesignating paragraphs (2) and (3) as paragraphs (1) and (2) respectively;
This change is to a provision the US Code prints only as a note, not as part of its text.
(C) in the matter preceding paragraph (1), as so redesignated, by striking the period at the end and inserting including—;
This change is to a provision the US Code prints only as a note, not as part of its text.
(D) by amending paragraph (1), as so redesignated, to read as follows:
(1) a description of how data generated through the proposed expanded access grant will be used to support research or development related to the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis;
;
This change is to a provision the US Code prints only as a note, not as part of its text.
(E) in paragraph (2), as so redesignated—
(i) by striking Noninterference with clinical trials— and all that follows through shall include;
This change is to a provision the US Code prints only as a note, not as part of its text.
(ii) by striking program and inserting grant; and
This change is to a provision the US Code prints only as a note, not as part of its text.
(iii) by striking the period at the end and inserting ; and; and
This change is to a provision the US Code prints only as a note, not as part of its text.
(F) by adding at the end the following:
(3) an assurance that such entity will promptly report to the Secretary available safety data from any ongoing clinical trial of the investigational drug as set forth in the terms and conditions of the grant.
;
This change is to a provision the US Code prints only as a note, not as part of its text.
(3) in subsection (c)—
(A) by redesignating subparagraphs (A) and (B) of paragraph (2) as clauses (i) and (ii), respectively, and adjusting the margins accordingly;
We couldn't place this change in the Code: we can't yet read how this change is worded.
(B) by redesignating paragraphs (1) through (3) as subparagraphs (A) through (C), respectively, and adjusting the margins accordingly;
This change is to a provision the US Code prints only as a note, not as part of its text.
(C) in subparagraph (C), as so redesignated, by striking the period at the end and inserting ; and;
This change is to a provision the US Code prints only as a note, not as part of its text.
(D) in the matter preceding subparagraph (A), as so redesignated, by striking this section, confirm that— and inserting the following: “this section—
(1) confirm that—
; and
We couldn't place this change in the Code: we can't yet read how this change is worded.
(E) by adding at the end the following:
(2) in the case of a renewal of such a grant, request from the sponsor of the investigational new drug application involved, and assess, the enrollment, safety, and any available efficacy data of the drug related to the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis.
;
This change is to a provision the US Code prints only as a note, not as part of its text.
(4) in subsection (d)(1), by striking request described in subsection (a) and inserting grant; and
This change is to a provision the US Code prints only as a note, not as part of its text.
(5) in subsection (e)—
(A) in paragraph (2), by inserting , and that begins enrollment within a timeframe as determined by the Secretary through the terms and conditions of the grant before the period at the end; and
This change is to a provision the US Code prints only as a note, not as part of its text.
(B) by adding at the end the following:
(4) The term “phase 3 clinical trial” includes a phase 2/3 combined trial and a planned phase 3 clinical trial that is not yet enrolling participants.
.
This change is to a provision the US Code prints only as a note, not as part of its text.
Sec. 4. Report on ALS and other rare neurodegenerative disease action plans Section 4 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360aa note) is amended—
(1) in the section heading, by striking ALS and other and inserting FDA;
This change is to a provision the US Code prints only as a note, not as part of its text.
(2) in subsection (a), in the matter preceding paragraph (1)—
(A) by inserting and not later than 1 year after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 and every 5 years thereafter, after this Act,; and
This change is to a provision the US Code prints only as a note, not as part of its text.
(B) by inserting develop, or update, as applicable, and before publish on;
This change is to a provision the US Code prints only as a note, not as part of its text.
(3) in subsection (b)—
(A) in the matter preceding paragraph (1), by striking initial;
This change is to a provision the US Code prints only as a note, not as part of its text.
(B) in paragraph (2)—
(i) in subparagraph (A), by inserting of relevant investigational new drug applications after sponsors;
This change is to a provision the US Code prints only as a note, not as part of its text.
(ii) in subparagraph (C) by inserting for the prevention, diagnosis, mitigation, treatment, or cure of rare neurodegenerative diseases before the semicolon; and
This change is to a provision the US Code prints only as a note, not as part of its text.
(iii) in subparagraph (D), by striking ; and and inserting a semicolon;
This change is to a provision the US Code prints only as a note, not as part of its text.
(C) in paragraph (3), by striking the period at the end and inserting ; and; and
This change is to a provision the US Code prints only as a note, not as part of its text.
(D) by adding at the end the following:
(4) for each action plan published after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, include a description of—
(A) previous actions taken by the Food and Drug Administration to implement the previous action plan published under subsection (a);
(B) any other planned actions to implement such action plan; and
(C) any barriers to implementing such action plan and related recommendations, which may include an estimate of resources necessary to address such barriers.
.
This change is to a provision the US Code prints only as a note, not as part of its text.
Sec. 5. Reports Section 6 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117–79) is amended—
(1) in the heading, by striking GAO Report and inserting Reports;
This change is to a law outside the US Code: the bill cites it only by Public Law number.
(2) by striking Not later than and inserting the following:
(a) GAO report.— Not later than
;
This change is to a law outside the US Code: the bill cites it only by Public Law number.
(3) in the matter preceding paragraph (1) of subsection (a), as so designated, by striking this Act and inserting the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026; and
This change is to a law outside the US Code: the bill cites it only by Public Law number.
(4) by adding at the end the following:
(b) HHS report.— Not later than 4 years after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, the Secretary of Health and Human Services shall, in a manner that does not duplicate the information described in the action plan published pursuant to section 4, submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report assessing the effectiveness of the activities carried out under sections 2, 3, and 5 and making recommendations to improve such activities.
.
This change is to a law outside the US Code: the bill cites it only by Public Law number.
Sec. 6. Technical amendments Section 3 of the Accelerating Access to Critical Therapies for ALS Act (42 U.S.C. 280g–7b) is amended—
(1) in subsection (a), in the matter preceding paragraph (1), by striking amytrophic and inserting amyotrophic; and
(2) in subsection (b)(3)(A)(iii), by striking rational.